{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:24:56Z","timestamp":1793582696759,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-ioi240014-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Experimental and observational studies have suggested that empirical treatment for bacterial sepsis with antianaerobic antibiotics (eg, piperacillin-tazobactam) is associated with adverse outcomes compared with anaerobe-sparing antibiotics (eg, cefepime). However, a recent pragmatic clinical trial of piperacillin-tazobactam and cefepime showed no difference in short-term outcomes at 14 days. Further studies are needed to help clarify the empirical use of these agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240014-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the use of piperacillin-tazobactam compared with cefepime in 90-day mortality in patients treated empirically for sepsis, using instrumental variable analysis of a 15-month piperacillin-tazobactam shortage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240014-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In a retrospective cohort study, hospital admissions at the University of Michigan from July 1, 2014, to December 31, 2018, including a piperacillin-tazobactam shortage period from June 12, 2015, to September 18, 2016, were examined. Adult patients with suspected sepsis treated with vancomycin and either piperacillin-tazobactam or cefepime for conditions with presumed equipoise between piperacillin-tazobactam and cefepime were included in the study. Data analysis was conducted from December 17, 2022, to April 11, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240014-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was 90-day mortality. Secondary outcomes included organ failure\u2013free, ventilator-free, and vasopressor-free days. The 15-month piperacillin-tazobactam shortage period was used as an instrumental variable for unmeasured confounding in antibiotic selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240014-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 7569 patients (4174 men [55%]; median age, 63 [IQR 52-73] years) with sepsis meeting study eligibility, 4523 were treated with vancomycin and piperacillin-tazobactam and 3046 were treated with vancomycin and cefepime. Of patients who received piperacillin-tazobactam, only 152 (3%) received it during the shortage. Treatment groups did not differ significantly in age, Charlson Comorbidity Index score, Sequential Organ Failure Assessment score, or time to antibiotic administration. In an instrumental variable analysis, piperacillin-tazobactam was associated with an absolute mortality increase of 5.0% at 90 days (95% CI, 1.9%-8.1%) and 2.1 (95% CI, 1.4-2.7) fewer organ failure\u2013free days, 1.1 (95% CI, 0.57-1.62) fewer ventilator-free days, and 1.5 (95% CI, 1.01-2.01) fewer vasopressor-free days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240014-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. These findings suggest that the widespread use of empirical antianaerobic antibiotics in sepsis may be harmful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2024.0581","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:01:26Z","timestamp":1715598086000},"page":"769","source":"Crossref","is-referenced-by-count":82,"title":["Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime"],"prefix":"10.1001","volume":"184","author":[{"given":"Rishi","family":"Chanderraj","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Medicine Service, Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Admon","sequence":"additional","affiliation":[{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nuppnau","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen R.","family":"Albin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie C.","family":"Prescott","sequence":"additional","affiliation":[{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Dickson","sequence":"additional","affiliation":[{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sjoding","sequence":"additional","affiliation":[{"name":"Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ioi240014r1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"ioi240014r3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/jama.2015.1410","article-title":"Readmission diagnoses after hospitalization for severe sepsis and other acute medical conditions.","volume":"313","author":"Prescott","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"ioi240014r4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jama.2014.5804","article-title":"Hospital deaths in patients with sepsis from 2 independent cohorts.","volume":"312","author":"Liu","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"ioi240014r5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.2016.20468","article-title":"Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions.","volume":"317","author":"Mayr","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"ioi240014r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7571","article-title":"Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals.","volume":"2","author":"Rhee","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ioi240014r7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/cid\/ciab170","article-title":"Antibiotic use and presumptive pathogens in the Veterans Affairs healthcare system.","volume":"74","author":"Tedijanto","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ioi240014r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2899","article-title":"Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use.","volume":"3","author":"Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ioi240014r9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamainternmed.2022.2291","article-title":"Temporal trends in antimicrobial prescribing during hospitalization for potential infection and sepsis.","volume":"182","author":"Prescott","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"9","key":"ioi240014r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23950","article-title":"Temporal trends and hospital variation in time-to-antibiotics among veterans hospitalized with sepsis.","volume":"4","author":"Wayne","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"ioi240014r11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/civ629","article-title":"Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010.","volume":"61","author":"Jones","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ioi240014r12","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/cid\/ciaa373","article-title":"Antimicrobial use in US Hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011.","volume":"72","author":"Magill","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ioi240014r13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America.","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ioi240014r14","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ioi240014r15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America.","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ioi240014r16","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ioi240014r17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cid\/ciy936","article-title":"Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in intensive care unit patients.","volume":"69","author":"Pettigrew","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"339","key":"ioi240014r18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2311","article-title":"Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.","volume":"8","author":"Shono","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"ioi240014r19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00910-2022","article-title":"In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes.","volume":"61","author":"Chanderraj","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"ioi240014r20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00413-2023","article-title":"Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes in emergency department patients.","volume":"61","author":"Kullberg","year":"2023","journal-title":"Eur Respir J"},{"issue":"7","key":"ioi240014r21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/cix947","article-title":"Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure.","volume":"66","author":"Baggs","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ioi240014r22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1086\/652985","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use.","volume":"51","author":"Leibovici","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ioi240014r23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis.","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"ioi240014r24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/jcpt.v47.11","article-title":"The association between empiric antimicrobial therapy and the risk of clinical failure in critically ill patients with aspiration pneumonia.","volume":"47","author":"Brumit","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"16","key":"ioi240014r25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial.","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"ioi240014r26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1078155220918638","article-title":"Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia.","volume":"27","author":"Haiduc","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"ioi240014r27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01980-20","article-title":"Consecutive antibiotic shortages highlight discrepancies between microbiology and prescribing practices for intra-abdominal infections.","volume":"95","author":"Park","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"ioi240014r28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2017.2841","article-title":"Association between US norepinephrine shortage and mortality among patients with septic shock.","volume":"317","author":"Vail","year":"2017","journal-title":"JAMA"},{"issue":"13","key":"ioi240014r29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"},{"key":"ioi240014r31","doi-asserted-by":"publisher","first-page":"k5092","DOI":"10.1136\/bmj.k5092","article-title":"Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study.","volume":"364","author":"Chua","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"ioi240014r32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"ioi240014r33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"5","key":"ioi240014r34","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/CCM.0b013e31819def97","article-title":"The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation.","volume":"37","author":"Jones","year":"2009","journal-title":"Crit Care Med"},{"issue":"6","key":"ioi240014r35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011347","article-title":"Early intervention of patients at risk for acute respiratory failure and prolonged mechanical ventilation with a checklist aimed at the prevention of organ failure: protocol for a pragmatic stepped-wedged cluster trial of PROOFCheck.","volume":"6","author":"Gong","year":"2016","journal-title":"BMJ Open"},{"issue":"17","key":"ioi240014r36","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial.","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"ioi240014r37","doi-asserted-by":"publisher","DOI":"10.2196\/36261","article-title":"Lessening Organ Dysfunction With Vitamin C (LOVIT) trial: statistical analysis plan.","volume":"11","author":"Adhikari","year":"2022","journal-title":"JMIR Res Protoc"},{"key":"ioi240014r38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/publhealth.1998.19.issue-1","article-title":"Econometrics in outcomes research: the use of instrumental variables.","volume":"19","author":"Newhouse","year":"1998","journal-title":"Annu Rev Public Health"},{"issue":"13","key":"ioi240014r39","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/sim.6128","article-title":"Instrumental variable methods for causal inference.","volume":"33","author":"Baiocchi","year":"2014","journal-title":"Stat Med"},{"issue":"12","key":"ioi240014r40","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jclinepi.2008.12.006","article-title":"Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance.","volume":"62","author":"Rassen","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"ioi240014r41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1017\/S0266466600006125","article-title":"Multiplicative panel data models without the strict exogeneity assumption.","volume":"13","author":"Wooldridge","year":"1997","journal-title":"Econ Theory"},{"key":"ioi240014r42","doi-asserted-by":"publisher","first-page":"l1927","DOI":"10.1136\/bmj.l1927","article-title":"Intensive care use and mortality among patients with ST elevation myocardial infarction: retrospective cohort study.","volume":"365","author":"Valley","year":"2019","journal-title":"BMJ"},{"issue":"25","key":"ioi240014r43","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.v28:25","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"ioi240014r44","author":"Durbin","year":"1954","journal-title":"Int Stat Rev"},{"key":"ioi240014r45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2307\/1914093","article-title":"Alternative tests of independence between stochastic regressors and disturbances.","author":"Wu","year":"1973","journal-title":"Econometrica"},{"key":"ioi240014r46","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2307\/1913827","article-title":"Specification tests in econometrics.","author":"Hausman","year":"1978","journal-title":"Econometrica"},{"issue":"5, pt 1","key":"ioi240014r47","first-page":"1337","article-title":"Who is the marginal patient? understanding instrumental variables estimates of treatment effects.","volume":"33","author":"Harris","year":"1998","journal-title":"Health Serv Res"},{"issue":"12","key":"ioi240014r48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jama.2015.11068","article-title":"Association of intensive care unit admission with mortality among older patients with pneumonia.","volume":"314","author":"Valley","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"ioi240014r49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/gutjnl-2015-309728","article-title":"The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia.","volume":"65","author":"Schuijt","year":"2016","journal-title":"Gut"},{"key":"ioi240014r2","unstructured":"Liang? L, Moore? B, Soni? A. National inpatient hospital costs: the most expensive conditions by payer, 2017. Healthcare Cost and Utilization Project Statistical Briefs: Agency for Healthcare Research and Quality; July 2020. Statistical brief 261. Accessed March 25, 2024. . https:\/\/hcup-us.ahrq.gov\/reports\/statbriefs\/sb261-Most-Expensive-Hospital-Conditions-2017.jsp#:~:text=In%202017%2C%20aggregate%20hospital%20costs,myocardial%20infarction%2C%20and%20heart%20failure"},{"key":"ioi240014r30","unstructured":"Centers for Disease Control and Prevention. CDC hospital toolkit for adult sepsis surveillance. May 2018. Accessed September 12, 2023. https:\/\/www.cdc.gov\/sepsis\/pdfs\/Sepsis-Surveillance-Toolkit-Aug-2018_508.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2818278\/jamainternal_chanderraj_2024_oi_240014_1719497546.29238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T11:08:46Z","timestamp":1719832126000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2818278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2024.0581","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}